Replies to post #86438 on Biotech Values

[poorgradstudent]

This trial design can address the biological feedback of LDL levels when you try to modulate HDL using the CETP inhibitor alone. This arm also allows the sponsor to determine if the CETP inhibitor alone brings LDL down into the target range for benefit (~100ish mg/dL).

The mix of CETPi and a statin is probably more of a "real world" situation that they want to monitor. It also allows them to see if they can push for even lower LDL, since there is an imaginary belief (and real obsession) among many cardiologists that the lower the LDL, the better.